Agile Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
September 14 2017 - 07:45AM
Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s health specialty
pharmaceutical company, announced today that Al Altomari, Chairman
and CEO, will present at the Cantor Fitzgerald Global Healthcare
Conference on Tuesday, September 26th, 2017 at 11:30 AM Eastern
Time in New York City.
To access the live and archived webcast of the
presentation, visit the Investor Relations section of Agile
Therapeutics website at www.agiletherapeutics.com. The
webcast will be archived on Agile Therapeutics website for 60 days
following the event.
About Agile TherapeuticsAgile
Therapeutics is a forward-thinking women's healthcare company
dedicated to fulfilling the unmet health needs of today’s women.
Our product candidates are designed to provide women with
contraceptive options that offer freedom from taking a daily pill,
without committing to a longer-acting method. Our lead product
candidate, Twirla®, (ethinyl estradiol and levonorgestrel
transdermal system), also known as AG200-15, is a once-weekly
prescription contraceptive patch that recently completed Phase 3
trials. Twirla is based on our proprietary transdermal patch
technology, called Skinfusion®, which is designed to provide
advantages over currently available patches and is intended to
optimize patch adhesion and patient wearability. For more
information, please visit the company website at
www.agiletherapeutics.com. Follow Agile on Twitter: @agilether. The
company may occasionally disseminate material, nonpublic
information on the company website.
About
Twirla®Twirla (ethinyl estradiol and
levonorgestrel transdermal system) or AG200-15 is an
investigational once-weekly prescription contraceptive patch.
AG200-15 is a combined hormonal contraceptive (CHC) patch that
contains the active ingredients ethinyl estradiol (EE), a synthetic
estrogen, and levonorgestrel (LNG), a type of progestin, a
synthetic steroid hormone. Twirla is designed to be applied once
weekly for three weeks, followed by a week without a patch.
Contact:
Mary Coleman - 609-683-1880
Investor Relations, Agile Therapeutics, Inc.
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Mar 2023 to Mar 2024